Jason Pharmaceuticals product receives certification by The Glycemic Research Institute

- Last updated on GMT

Related tags: Diabetes mellitus

Medifast Plus for Diabetics has been approved as "low glycemic",
making it more valuable to athletes and diabetics.

The Jason Pharmaceuticals product, Medifast Plus for Diabetics, has been approved as "low glycemic", according to the Glycemic Research Institute in Washington.

The Institute's Seal of Approval designates that a food does not overly stimulate blood glucose and insulin and does not stimulate fat-storing enzymes.

The seal is used by those with insulin-related disorders, such as syndrome X, insulin-resistance, diabetes and hypoglycemia, who must be careful to only select insulin-friendly products .

Athletes and those dieting also try and avoid "high glycemic" foods since they stimulate insulin and fat-storage. Medifast claims that the Seal of Approval makes it easy for consumers to distinguish "high glycemic" foods from those that are "low glycemic".

"Low glycemic" products do not imbalance blood sugar levels, important for athletes in competitions, who will be negatively affected by "high glycemic" food, drinks, and nutraceuticals products.

Jason Pharmaceuticals is a subsidiary of Medifast.

Related topics: Research, Suppliers

Follow us

Products

View more

Webinars